Variable
|
Univariate analysis
|
Multivariate analysis
|
---|
|
p
|
Hazard ratio (95 % CI)
|
Estimate
|
SE
|
p
|
Hazard ratio (95 % CI))
|
---|
CR/PR vs SD/PD
|
<0.001
|
0.23 (0.12–0.45)
|
−1.30
|
0.37
|
<0.001
|
0.27 (0.13–0.56)
|
Second-line chemotherapy none vs done
|
<0.001
|
3.60 (2.03–6.37)
|
0.98
|
0.40
|
0.013
|
2.67 (1.23–5.78)
|
GS none vs done
|
0.009
|
2.05 (1.19–3.52)
|
0.21
|
0.34
|
0.53
|
1.24 (0.64–2.39)
|
Radiation none vs done
|
0.009
|
2.21 (1.22–4.01)
|
0.13
|
0.39
|
0.73
|
1.14 (0.53–2.45)
|
No ascites vs development of ascites at 1 year
|
<0.001
|
0.39 (0.23–0.65)
|
−0.12
|
0.31
|
0.70
|
0.89 (0.48–1.63)
|
LA/CY vs P/L
|
0.015
|
0.51 (0.30–0.88)
|
−0.11
|
0.32
|
0.72
|
0.89 (0.48–1.68)
|
-
CI confidential interval, SE standard and error, CR complete response, PR partial response, SD stable disease, PD progressive disease, GS gemcitabine and S-1, LA locally advanced, CY positive cytology, P peritoneal metastasis, L liver metastasis, CTx chemotherapy, BSC best supportive care